Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RANEE MEHRA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1760411326
CMS profile
170140
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$4,211.09

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,050.00 2
Food and Beverage $161.09 3

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Coherus Biosciences Inc. $4,171.44 3
EISAI INC. $23.36 1
Gilead Sciences, Inc. $16.29 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RANEE MEHRA

NPI 1760411326 · CMS profile ID 170140

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760411326?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760411326?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760411326?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RANEE MEHRA, NPI 1760411326, CMS profile ID 170140, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1760411326?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $4,211.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EISAI INC. $23.3608/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908078449 CMS
Coherus Biosciences Inc. $121.4406/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956565101 CMS
Coherus Biosciences Inc. $1,687.5004/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956565039 CMS
Gilead Sciences, Inc. $16.2903/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929559295 CMS
Coherus Biosciences Inc. $2,362.5002/24/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956565053 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,242.50 5
PY2022 $4,211.09 5
PY2023 $917.82 20
PY2024 $2,617.99 14
PY2025 $273.81 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,124,333.75 93
PY2024 Principal investigator $813,892.28 61
PY2023 Principal investigator $633,471.41 125
PY2022 Principal investigator $830,697.81 139
PY2021 Recipient $330.00 1
PY2021 Principal investigator $979,164.73 91
PY2020 Principal investigator $622,730.93 67
PY2019 Principal investigator $214,554.45 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

92 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $688.08 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826469789
Principal investigator 1 AstraZeneca Pharmaceuticals LP $395.81 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND DEPARTMENT OF PHARMACEUTICAL HEALTH SERVICES RESEARCH
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826486381
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,600.59 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826494169
Principal investigator 1 AstraZeneca Pharmaceuticals LP $392.46 12/31/2021 Non-covered Recipient Entity
UNIV OF MARYLAND BALTIMORE
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826494473
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,109.70 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826495619
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,149.04 12/31/2021 Non-covered Recipient Entity
UNIV OF MARYLAND
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826503743
Principal investigator 1 Merck Sharp & Dohme Corporation $21,627.74 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy for Advanced Non Small Cell Lung Cancer KEYNOTE-495 KeyImPaCT No dispute reported 06/30/2026 848746411
Principal investigator 1 Merck Sharp & Dohme Corporation $13,125.66 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy for Advanced Non Small Cell Lung Cancer KEYNOTE-495 KeyImPaCT No dispute reported 06/30/2026 848746451
Principal investigator 1 Merck Sharp & Dohme Corporation $12,755.03 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 848748439
Principal investigator 1 Merck Sharp & Dohme Corporation $84,686.15 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 848748441
Principal investigator 1 Merck Sharp & Dohme Corporation $15,152.54 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 848755875
Principal investigator 1 Merck Sharp & Dohme Corporation $20,305.65 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 848755877
Principal investigator 1 Merck Sharp & Dohme Corporation $60,404.16 12/31/2021 Non-covered Recipient Entity
U OF MARYLAND
Phase II Study of pembrolizumab and bavituximab for recurrent,metastatic SCCN No dispute reported 06/30/2026 848759303
Principal investigator 1 Seagen Inc. $812.50 12/22/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792655965
Principal investigator 1 Merck Sharp & Dohme Corporation $35,628.16 12/15/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 848755873
Principal investigator 1 EMD Serono, Inc. $674.90 12/07/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842917339
Principal investigator 1 EMD Serono, Inc. $1,815.00 12/07/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842917463
Principal investigator 1 EMD Serono, Inc. $622.90 12/07/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842917473
Principal investigator 1 EMD Serono, Inc. $3,824.00 12/07/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842917735
Principal investigator 1 Merck Sharp & Dohme Corporation $51,705.00 12/03/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 848748437
Principal investigator 1 Novocure Inc. $3,997.50 12/03/2021 Non-covered Recipient Entity
University of Maryland Baltimore
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 827905309
Principal investigator 1 Merck Sharp & Dohme Corporation $164,084.90 11/16/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND MARLENE AND STEWART GREENEBAUM CANCER CENTER
A Phase II, Open-Label, Multi-Center Trial of PDS0101 ImmunoMAPK-RDOTAP,HPV-16 E6 & E7 peptides and Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Cancer and High-risk Human Papillomavirus-16 HPV16 Infection after Failure with Platinum-Based Chemotherapy No dispute reported 06/30/2026 848759405
Principal investigator 1 MACROGENICS, INC. $9,208.75 10/27/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
SAFETY STUDY OF ENOBLITUZUMAB MGA271 IN COMBINATION WITH PEMBROLIZUMAB OR MGA012 IN REFRACTORY CANCER No dispute reported 06/30/2026 838714061
Principal investigator 1 MACROGENICS, INC. $3,918.62 10/27/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
SAFETY STUDY OF ENOBLITUZUMAB MGA271 IN COMBINATION WITH PEMBROLIZUMAB OR MGA012 IN REFRACTORY CANCER No dispute reported 06/30/2026 838714067
Principal investigator 1 MACROGENICS, INC. $6,465.72 10/27/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
SAFETY STUDY OF ENOBLITUZUMAB MGA271 IN COMBINATION WITH PEMBROLIZUMAB OR MGA012 IN REFRACTORY CANCER No dispute reported 06/30/2026 838714073
Principal investigator 1 Novocure Inc. $812.50 09/16/2021 Non-covered Recipient Entity
University of Maryland Baltimore
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 827905303
Principal investigator 1 EMD Serono, Inc. $998.00 09/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842910837
Principal investigator 1 Incyte Corporation $1,300.00 08/27/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097545
Principal investigator 1 Incyte Corporation $7,000.00 08/27/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097551
Principal investigator 1 Incyte Corporation $4,705.00 08/27/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097557
Principal investigator 1 Incyte Corporation $3,900.00 08/27/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097563
Principal investigator 1 Incyte Corporation $283.00 08/27/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097569
Principal investigator 1 Incyte Corporation $3,055.00 08/27/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097575
Principal investigator 1 Incyte Corporation $1,950.00 08/27/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097581
Principal investigator 1 Seagen Inc. $812.50 08/11/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792655915
Principal investigator 1 Incyte Corporation $25.02 08/09/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097591
Principal investigator 1 Incyte Corporation $20.26 08/09/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097597
Principal investigator 1 Incyte Corporation $116.40 08/09/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097603
Principal investigator 1 EMD Serono, Inc. $585.00 08/02/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842907823
Principal investigator 1 EMD Serono, Inc. $863.00 08/02/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842909007
Principal investigator 1 EMD Serono, Inc. $2,415.00 08/02/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842913851
Recipient PFIZER INC. $330.00 07/29/2021 Covered Recipient Physician SASANLIMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 832564969
Principal investigator 1 Novocure Inc. $4,615.00 07/22/2021 Non-covered Recipient Entity
University of Maryland Baltimore
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 827905291
Principal investigator 1 PFIZER INC. $89.21 07/21/2021 Non-covered Recipient Entity
University of Maryland Greenebaum Comprehensive Ca
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF SASANLIMAB COMBINED WITH ANTICANCER THERAPIES TARGETING MULTIPLE MOLECULAR MECHANISMS IN PARTICIPANTS WITH NONSMALL CELL LUNG CANCER NSCLC No dispute reported 06/30/2026 832800701
Principal investigator 1 Seagen Inc. $2,600.00 07/21/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792655913
Principal investigator 1 PFIZER INC. $15,592.50 07/08/2021 Non-covered Recipient Entity
University of Maryland Baltimore
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06939999 PRMT5 INHIBITOR IN PARTICIPANTS WITH ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA ESOPHAGEAL CANCER ENDOMETRIAL CANCER CERVICAL CANCER AND BLADDER CANCER No dispute reported 06/30/2026 832689059
Principal investigator 1 Seagen Inc. $130.00 07/07/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792655917
Principal investigator 1 Seagen Inc. $7,247.50 07/07/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792655919
Principal investigator 1 Eli Lilly and Company $18,393.30 06/23/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1 STUDY OF ORAL LOXO-292 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS HARBORING RET ALTERATIONS No dispute reported 06/30/2026 819470333
Principal investigator 1 EMD Serono, Inc. $2,589.00 06/16/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842927781
Principal investigator 1 EMD Serono, Inc. $2,415.00 06/16/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842927787
Principal investigator 1 EMD Serono, Inc. $24,310.00 06/16/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842928019
Principal investigator 1 EMD Serono, Inc. $650.00 06/16/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842928271
Principal investigator 1 EMD Serono, Inc. $390.00 06/16/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842928355
Principal investigator 1 EMD Serono, Inc. $390.00 06/16/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842928391
Principal investigator 1 EMD Serono, Inc. $2,340.00 06/16/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non small Cell Lung Cancer No dispute reported 06/30/2026 842928953
Principal investigator 1 AstraZeneca UK Limited $1,725.00 06/14/2021 Non-covered Recipient Entity
UNIV OF MD MED SYSTEM PHS
An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE No dispute reported 06/30/2026 826457215
Principal investigator 1 AstraZeneca UK Limited $3,669.80 06/14/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE No dispute reported 06/30/2026 826489721
Principal investigator 1 AstraZeneca UK Limited $1,773.34 06/07/2021 Non-covered Recipient Entity
UNIV OF MARYLAND BALTIMORE
An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE No dispute reported 06/30/2026 826451041
Principal investigator 1 AstraZeneca UK Limited $5,005.09 06/07/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE No dispute reported 06/30/2026 826488409
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,014.00 05/28/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND DEPARTMENT OF PHARMACEUTICAL HEALTH SERVICES RESEARCH
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826489919
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,978.96 05/28/2021 Non-covered Recipient Entity
UNIV OF MARYLAND
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826490545
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,450.00 05/28/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826501331
Principal investigator 1 Merck Sharp & Dohme Corporation $260,000.00 05/25/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND MEDICAL CENTER
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 848768609
Principal investigator 1 Incyte Corporation $64.32 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097429
Principal investigator 1 Incyte Corporation $91.89 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097435
Principal investigator 1 Incyte Corporation $12.30 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097441
Principal investigator 1 Incyte Corporation $1.08 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097447
Principal investigator 1 Incyte Corporation $15.64 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097453
Principal investigator 1 Incyte Corporation $2.97 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097459
Principal investigator 1 Incyte Corporation $30.63 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097465
Principal investigator 1 Incyte Corporation $116.40 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097471
Principal investigator 1 Incyte Corporation $75.06 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097477
Principal investigator 1 Incyte Corporation $30.92 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097482
Principal investigator 1 Incyte Corporation $12.24 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097487
Principal investigator 1 Incyte Corporation $65.89 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097493
Principal investigator 1 Incyte Corporation $1.56 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097499
Principal investigator 1 Incyte Corporation $6.39 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097505
Principal investigator 1 Incyte Corporation $2.84 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097511
Principal investigator 1 Incyte Corporation $35.16 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097517
Principal investigator 1 Incyte Corporation $10.20 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097523
Principal investigator 1 Incyte Corporation $20.26 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097529
Principal investigator 1 Incyte Corporation $24.08 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097535
Principal investigator 1 Incyte Corporation $64.32 05/10/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 831097539
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,188.00 05/07/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826492095
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,988.50 04/30/2021 Non-covered Recipient Entity
UNIV OF MARYLAND BALTIMORE
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826459455
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,239.50 04/30/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 826468367
Principal investigator 1 AstraZeneca UK Limited $30.68 04/21/2021 Non-covered Recipient Entity
UNIV OF MARYLAND
An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE No dispute reported 06/30/2026 826477661
Principal investigator 1 AstraZeneca UK Limited $2,469.94 04/21/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE
An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE No dispute reported 06/30/2026 826490347
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,600.00 04/13/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b 2a Multi Center Open Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 INO 3112 and Durvalumab MEDI4736 in Patients with Recurrent Metastatic Human Papilloma Virus Associated Head and Neck Squamous Cancer No dispute reported 06/30/2026 826471507
Principal investigator 1 Seagen Inc. $362.00 04/07/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792655865
Principal investigator 1 Seagen Inc. $10,243.02 02/03/2021 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792655849